Atrial fibrillation (AF) is the most common cardiac arrhythmia. Developing effective and safe anti-AF drugs remains an unmet challenge. Simultaneous block of both atrial-specific ultra-rapid delayed rectifier potassium (K+) current (IKur) and the Na+ current (INa) has been hypothesized to be anti-AF, without inducing significant QT prolongation and ventricular side effects. However, the antiarrhythmic advantage of simultaneously blocking these two channels vs. individual block in the setting of AF-induced electrical remodeling remains to be documented. Furthermore, many IKur blockers such as acacetin and AVE0118, partially inhibit other K+ currents in the atria. Whether this multi-K+-block produces greater anti-AF effects compared with sele...
Poster presentationBackground and objective: We have recently demonstrated that the natural flavone ...
AIMS: We aimed at examining the acetylcholine-dependent inward-rectifier current (IKAch) as a target...
Selective blockers of the Kv1.5 channel have been developed for the treatment of atrial fibrillation...
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Developing effective and safe anti-A...
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Developing effective and safe anti-A...
International audienceAims: Recent clinical studies showed that antiarrhythmic drug (AAD) treatment ...
Atrial fibrillation (AF) is the most common tachyarrhythmia in the adult population and is a major c...
Current pharmacological therapy against atrial fibrillation (AF), the most common cardiac arrhythmia...
BACKGROUND - The development of atrium-selective antiarrhythmic agents is a current strategy for inh...
In the wake of demographic change in Western countries atrial fibrillation has reached an epidemiolo...
This invention provides a method for treating or preventing human atrial arrhythmia (fibrillation) u...
Inhibition of the atrial ultra-rapid delayed rectifier potassium current (IKur) represents a promisi...
There is increasing evidence on the role of the autonomic nervous system in the pathogenesis of atri...
Aims: Atrial anti-arrhythmic effects of β-adrenoceptor antagonists (β-blockers) may involve both a s...
By sensing changes in intracellular Ca , small-conductance Ca -activated K (SK) channels dynamically...
Poster presentationBackground and objective: We have recently demonstrated that the natural flavone ...
AIMS: We aimed at examining the acetylcholine-dependent inward-rectifier current (IKAch) as a target...
Selective blockers of the Kv1.5 channel have been developed for the treatment of atrial fibrillation...
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Developing effective and safe anti-A...
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Developing effective and safe anti-A...
International audienceAims: Recent clinical studies showed that antiarrhythmic drug (AAD) treatment ...
Atrial fibrillation (AF) is the most common tachyarrhythmia in the adult population and is a major c...
Current pharmacological therapy against atrial fibrillation (AF), the most common cardiac arrhythmia...
BACKGROUND - The development of atrium-selective antiarrhythmic agents is a current strategy for inh...
In the wake of demographic change in Western countries atrial fibrillation has reached an epidemiolo...
This invention provides a method for treating or preventing human atrial arrhythmia (fibrillation) u...
Inhibition of the atrial ultra-rapid delayed rectifier potassium current (IKur) represents a promisi...
There is increasing evidence on the role of the autonomic nervous system in the pathogenesis of atri...
Aims: Atrial anti-arrhythmic effects of β-adrenoceptor antagonists (β-blockers) may involve both a s...
By sensing changes in intracellular Ca , small-conductance Ca -activated K (SK) channels dynamically...
Poster presentationBackground and objective: We have recently demonstrated that the natural flavone ...
AIMS: We aimed at examining the acetylcholine-dependent inward-rectifier current (IKAch) as a target...
Selective blockers of the Kv1.5 channel have been developed for the treatment of atrial fibrillation...